RxDoctor Payments Data

Sanjeev Venkataraman, MD

Psychiatry · Bloomfield Township, MINPI 1629120282

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $373 of the $420 with a category attached, or 88.8%. 8 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 38.0% of the total. Reporting peaked in 2024 at $168 and has fallen 71.6% since, to $48 in 2025.

$420in general payments, 2019–2025

Across 22 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$160
  • Sunovion Pharmaceuticals Inc.$90
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
  • Supernus Pharmaceuticals, Inc.$32
  • Corium, LLC$31
  • Ironshore Pharmaceuticals Inc.$28
  • plus $32 from 2 others
$8,433in research payments, 2019–2025

Across 6 payments — averaging $1405.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sunovion Pharmaceuticals Inc.$8K

What the payments were for

  • Food & beverage$37389%
  • Education$4711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$420 in reported general payments places this provider in the 60th percentile of 1,166 psychiatry providers in Michigan.

See all psychiatry providers in Michigan →

Medicare billing

Part B allowed, 2024
$9,816
Medicare patients
12
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide24$12,154
Paliperidone ErPaliperidone24$7,156
Risperidone OdtRisperidone25$1,483
Clozapine24$1,157
Aripiprazole40$992
Quetiapine Fumarate19$721
Duloxetine Hcl49$594
Buspirone Hcl42$474
Bupropion XlBupropion Hcl16$405
Topiramate12$264
Fluoxetine Hcl31$181
Lorazepam15$176
Clonazepam27$107
Sertraline Hcl12$61

Paid to pharmacies, not to this prescriber.

Other psychiatry in Bloomfield Township

See the full list for Michigan →

Where these figures come from

Is this you, or does something look wrong? →